- Home
- SDGR vs TARS Comparison
SDGR vs TARS Comparison
Compare SDGR & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDGR
- TARS
- Stock Information
- Founded
- SDGR 1990
- TARS 2016
- Country
- SDGR United States
- TARS United States
- Employees
- SDGR N/A
- TARS N/A
- Industry
- SDGR Biotechnology: Pharmaceutical Preparations
- TARS Medicinal Chemicals and Botanical Products
- Sector
- SDGR Health Care
- TARS Health Care
- Exchange
- SDGR Nasdaq
- TARS Nasdaq
- Market Cap
- SDGR 1.7B
- TARS 1.8B
- IPO Year
- SDGR 2020
- TARS 2020
- Fundamental
- Price
- SDGR $20.46
- TARS $40.65
- Analyst Decision
- SDGR Buy
- TARS Strong Buy
- Analyst Count
- SDGR 5
- TARS 7
- Target Price
- SDGR $32.80
- TARS $67.14
- AVG Volume (30 Days)
- SDGR 1.2M
- TARS 552.3K
- Earning Date
- SDGR 07-30-2025
- TARS 08-07-2025
- Dividend Yield
- SDGR N/A
- TARS N/A
- EPS Growth
- SDGR N/A
- TARS N/A
- EPS
- SDGR N/A
- TARS N/A
- Revenue
- SDGR $230,492,000.00
- TARS $233,674,000.00
- Revenue This Year
- SDGR $24.44
- TARS $122.94
- Revenue Next Year
- SDGR $22.17
- TARS $44.14
- P/E Ratio
- SDGR N/A
- TARS N/A
- Revenue Growth
- SDGR 22.29
- TARS 449.03
- 52 Week Low
- SDGR $16.60
- TARS $20.08
- 52 Week High
- SDGR $28.47
- TARS $57.28
- Technical
- Relative Strength Index (RSI)
- SDGR 37.57
- TARS 40.26
- Support Level
- SDGR $20.90
- TARS $39.25
- Resistance Level
- SDGR $21.62
- TARS $42.01
- Average True Range (ATR)
- SDGR 1.37
- TARS 1.93
- MACD
- SDGR -0.35
- TARS -0.05
- Stochastic Oscillator
- SDGR 4.46
- TARS 22.95
About SDGR Schrodinger Inc.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.